Memorial Sloan Kettering to offer Dignicap® scalp cooling device in New York metro area locations

Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the U.S. FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all Memorial Sloan Kettering Cancer Center (MSK) facilities that treat breast cancer.

The DigniCap® system is the first and only scalp-cooling device to receive FDA clearance. In the rigorous FDA clinical trial, seven out of ten patients with early-stage breast cancer kept at least 50% of their hair. The demand for the FDA-cleared DigniCap® system has been significant this year in the United States.

MSK, a world leader in cancer patient care, research, and educational programs, will now have the 17 units ordered in December of 2016 available for use by female patients undergoing breast cancer treatment in eight of their outpatient facilities in the New York City area. These include MSK Basking Ridge and MSK Monmouth, in New Jersey; MSK Westchester, in Westchester County, New York; and MSK Commack and MSK Rockville Centre, on Long Island, in addition to their Manhattan and Brooklyn locations.

"Scalp cooling is clinically proven and can be an important tool for many women in treatment for breast cancer," says Mario Lacouture, MD, Director of the Oncodermatology Program at MSK. "As a world leader in comprehensive cancer care, we are proud to be able to offer our patients across the New York metro area this new FDA-cleared advancement that addresses one of the most distressing and most visible side effects of chemotherapy."

"Bringing the DigniCap® system to MSK is an important milestone for Dignitana," says William Cronin, Chief Executive Officer of Dignitana, Inc., the U.S. subsidiary of Dignitana AB. "We have just passed the one-year anniversary of clearance by the FDA for DigniCap® in the U.S., and we are proud to add Memorial Sloan Kettering, one of the top comprehensive cancer centers in the U.S., to the growing number of facilities that are providing this treatment option to patients on a large scale."

The DigniCap® clinical team is working directly with the clinical practitioners at each of the eight MSK sites to train and certify staff on the machine.  This is the largest scalp-cooling installation at any medical center to date in the U.S. Nearly 100 nurses and other medical personnel will be trained in preparation for the launch of this service at MSK in the Spring of 2017.

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch-screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

Lund, Sweden - February 13, 2017

Media Contacts:
Caren Browning
King + Company
+1 212 561-7464

Semmy Rülf
Chairman of the board
+46 (0)709 312730

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Advisor. Headquartered in Dallas, Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit

About Memorial Sloan Kettering
We are the world's oldest and largest private cancer center, home to more than 14,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to

Dignitana CEO William Cronin to Speak at Aktiedagen Stockholm

Dignitana AB announces that Chief Executive Officer William Cronin will speak at Aktiedagen Stockholm on 19 March 2019 at 15:00 CET.

Dignitana AB Taps oneservice as Service Provider in Europe

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, announces today that it has partnered with oneservice, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

Dignitana AB Publishes Year End Report for 2018

Results and financial position

Significant events during the period

  • Sales for the period amounted to 8,772 TSEK, $971 KUSD, an increase of 34 percent compared to the same period in 2017.
  • EBITDA amounted to (2,996) TSEK, ($335) KUSD, a 72 percent improvement compared to the same period in 2017.
  • U.S. annual revenue increased 52 percent over 2017.
  • Contracts for 8 units were placed globally.
  • Contracts were signed for 13 U.S. locations.
  • U.S. fourth quarter revenue increased 18 percent over fourth quarter 2017.
  • On 8 October Dignitana announced that Mr. Greg Dingizian, via his Adma Förvaltnings AB investment vehicle, had accumulated 10.4 percent of the outstanding common shares of the company.
  • On 14 November Dignitana announced the establishment of a clinical trial at Beijing University Cancer Hospital in conjunction with Konica Minolta.
  • In December the company completed rights and directed equity issues providing the Company with approximately SEK 33.8M before issue costs.

Rättelse - sista dag för handel med BTA i Dignitana AB (publ) är idag den 29 januari 2019

Sista dag för handel i Dignitanas betalda tecknade aktier, DIGN BTA, är tisdagen den 29 januari 2019. De nya aktierna beräknas att synas på VP-konton och depåer måndagen den 4 februari 2019.

Amendment - Last day of trading of paid-up shares in Dignitana AB (publ) is today, the 29 of January 2019

The last day of trading in Dignitana's paid-up shares, DIGN BTA, is Tuesday 29 January 2019. The new shares are estimated to be available in VP-accounts and depots Monday 4 February 2019.

Sista dag för handel med BTA i Dignitana AB (publ)

Sista dag för handel i Dignitanas betalda tecknade aktier, DIGN BTA, är onsdagen den 30 januari 2019. De nya aktierna beräknas att synas på VP-konton och depåer måndagen den 4 februari 2019.

Last day of trading of paid-up shares in Dignitana AB (publ)

The last day of trading in Dignitana's paid-up shares, DIGN BTA, is Wednesday 30 January 2019. The new shares are estimated to be available in VP-accounts and depots Monday 4 February 2019.

Dignitana offentliggör utfallet för företrädesemissionen och de riktade emissionerna

Teckningsperioden för Dignitana ABs ("Dignitana" eller "Bolaget") nyemission med företrädesrätt för Bolagets aktieägare löpte ut den 18 december 2018. Företrädesemissionen omfattades av teckningsförbindelser och garantiåtaganden upp till 100 procent av det totala emissionsbeloppet, som högst kunde uppgå till ca 24,3 MSEK. Utfallet visar att 5 383 686 aktier, motsvarande cirka 93 procent av Företrädesemissionen, tecknades med stöd av teckningsrätter och att 408 917 aktier, motsvarande cirka 7 procent av Företrädesemissionen, tecknades utan stöd av teckningsrätter. Totalt tecknades 1 517 201 aktier utan företrädesrätt innebärande att företrädesemissionen tecknades till ca 119 procent.   Genom företrädesemissionen tillförs Bolaget ca 24,3 MSEK före emissionskostnader. Emissionsgarantin har inte tagits i anspråk.

Dignitana Announces the Outcome of the Rights Issue and the Directed Issues

The subscription period for Dignitana AB's ("Dignitana" or "the Company") rights issue with preferential right for the Company's shareholders ended on 18 December 2018. The rights issue was covered by subscription commitments and guarantees up to 100 percent of the total amount in the Issue, corresponding to approximately SEK 24.3M. 5,383,686 shares, corresponding to 93 percent of the rights issue, was subscribed for with subscription rights and 408,917 shares, corresponding to approximately 7 percent of the rights issue, was subscribed for without subscription rights. In total, 1,517,201 shares were subscribed for without subscription right, implying that the rights issue was subscribed for to approximately 119 percent and the Company will receive approximately SEK 24.3M before issue costs. There will be no need to utilize the guarantee obligations that have been provided. 

Dignitana och ThermoTek har slutit avtal om kontraktsutveckling och produktion av nästa generations skalpkylningssystem

DigniCap Delta bygger på en avancerad kylteknik som minimerar håravfall vid kemoterapi

Dignitana AB, som tillverkar DigniCap® skalpkylningssystem, inleder ett samarbete med ThermoTek, Inc. för att utveckla DigniCap Delta, en avancerad modell av det FDA-godkända skalpkylningssystemet DigniCap från 2015. Den nya versionen är en mindre och smidigare enhet för behandling av en patient åt gången med en nydesignad, engångskylmössa.
FDA-godkännande för den nya enheten väntas komma under våren 2019.

Dignitana Partners with ThermoTek to Develop Next Generation in Scalp Cooling

DigniCap Delta brings advanced cooling technology to minimize hair loss from chemotherapy 

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has partnered with ThermoTek, Inc. to develop the DigniCap Delta, an advanced model of the 2015 FDA-cleared DigniCap Scalp Cooling System, featuring a new single-patient use cap design and a smaller, more streamlined single-patient machine. U.S. Food and Drug Adminstration clearance for the new device is anticipated in spring 2019.

Dignitana kompletterar den tidigare aviserade riktade emissionen med ytterligare en riktad emission

Styrelsen i Dignitana AB (publ) har idag beslutat, pga stort intresse, komplettera den tidigare aviserade riktade emissionen, genom att emittera ytterligare 540 000 aktier till ett belopp om 2,3 MSEK. Sammantaget innebär detta att de riktade emissionerna omfattar totalt 9,5 MSEK.

Dignitana complements the previously announced directed rights issue - decides on an additional directed rights issue

The Board of Directors of Dignitana AB (publ) has decided today, as a result of a large investor interest, to complement the previously announced directed rights issue by emitting 540,000 additional shares to an amount of approximately SEK 2.3M. In total this implies that the directed rights issues comprise a total of SEK 9.5M.

Dignitana offentliggör Informations-Memorandum

Styrelsen i Dignitana AB (publ) offentliggör härmed ett Informations-Memorandum med anledning av förestående företrädesemission. Memorandumet finns nu tillgängligt på bolagets hemsida,

Dignitana AB Publishes Information Memorandum

The Board of Directors of Dignitana AB (publ) hereby publishes an Information Memorandum on the announced rights issue. The Information Memorandum is attached here and is published today on the Company's webpage,

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: